ArticlePractical laboratory medicine2015
Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.
Article in Practical laboratory medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Pitfalls in the Diagnosis and Management of Hypercortisolism (Cushing Syndrome) in Humans; A Review of the Laboratory Medicine Perspective.Diagnostics (Basel, Switzerland) · 2023Review
- Comparison of two chromogranin A assays and investigation of nonlinear specimens.Practical laboratory medicine · 2022Article
- Performance Evaluation of the KRYPTOR Compact PLUS Analyzer-Based B.R.A.H.M.S. CgA Ⅱ KRYPTOR Assay for Chromogranin A Measurement.Diagnostics (Basel, Switzerland) · 2021Article
- Adrenal gland-released vasostatin-I is a myocardial depressant factor.British journal of clinical pharmacology · 2020Article
- Evaluation of CisBio ELISA for Chromogranin A Measurement.The journal of applied laboratory medicine · 2019Article
- Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.Endocrine connections · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChromogranin A (CgA) is a biomarker for neuroendocrine tumors (NETs). The aims of this study were to evaluate differences in measurement between the ThermoFisher Brahms CgA Kryptor assay and the CisBio assay and to investigate the influence of patient covariates. Temperature stability of CgA using both assays was determined. DESIGN AND
methods406 patients were analyzed for serum CgA using both assays. We performed a comparison study to determine whether several patient covariates (gender, use of protein pump inhibitors, impaired kidney function, referral department and tumor location) influenced the results. For the stability study, pooled serum samples were aliquoted and stored at different storage temperatures (room temperature, 4 °C and -20 °C) until assayed. In addition, 15 individual samples were evaluated after storage at 4 °C using the Kryptor assay.
resultsDifferences in measured concentrations between the assays were statistically significant. Passing & Bablok fit showed ln
conclusionDifferences in measured CgA concentration between the assays could not be explained by the investigated patient covariates. Serum should be stored at -20 °C prior to determination using the Kryptor assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.